CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 58 enrolled
Drug / intervention
Atorvastatindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02084069
NCT02084069Phase 3Completed
CompareCT.gov

Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair

Urmia University of Medical Sciences·interventional·Posted Mar 11, 2014·Updated Mar 4, 2015

In Brief

A Phase 3 clinical trial evaluating Atorvastatin for Heart Valve Diseases. Completed, enrolled 58 participants across 1 site.

Detailed Summary

The purpose of the investigation is to determine whether Atrovastatin as anti-inflammatory agent can be effective in preventing from atrial fibrillation incidence in patients whom undergone open cardiac surgery for their heart valve repair.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Valve Diseases
CountriesIran
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 11, 2014
Enrollment StartJan 1, 2013
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.3 years ago

Interventions

Atorvastatindrug